- Home
- TEI vs GOSS Comparison
TEI vs GOSS Comparison
Compare TEI & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEI
- GOSS
- Stock Information
- Founded
- TEI 1993
- GOSS 2015
- Country
- TEI United States
- GOSS United States
- Employees
- TEI N/A
- GOSS N/A
- Industry
- TEI Finance Companies
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- TEI Finance
- GOSS Health Care
- Exchange
- TEI Nasdaq
- GOSS Nasdaq
- Market Cap
- TEI 262.1M
- GOSS 212.9M
- IPO Year
- TEI N/A
- GOSS 2019
- Fundamental
- Price
- TEI $5.35
- GOSS $0.74
- Analyst Decision
- TEI
- GOSS Strong Buy
- Analyst Count
- TEI 0
- GOSS 5
- Target Price
- TEI N/A
- GOSS $9.20
- AVG Volume (30 Days)
- TEI 142.4K
- GOSS 881.6K
- Earning Date
- TEI 01-01-0001
- GOSS 11-07-2024
- Dividend Yield
- TEI 10.51%
- GOSS N/A
- EPS Growth
- TEI N/A
- GOSS N/A
- EPS
- TEI N/A
- GOSS N/A
- Revenue
- TEI N/A
- GOSS $105,322,000.00
- Revenue This Year
- TEI N/A
- GOSS N/A
- Revenue Next Year
- TEI N/A
- GOSS N/A
- P/E Ratio
- TEI N/A
- GOSS N/A
- Revenue Growth
- TEI N/A
- GOSS N/A
- 52 Week Low
- TEI $4.35
- GOSS $0.50
- 52 Week High
- TEI $5.39
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- TEI 37.73
- GOSS 22.63
- Support Level
- TEI $5.32
- GOSS $0.78
- Resistance Level
- TEI $5.63
- GOSS $0.92
- Average True Range (ATR)
- TEI 0.10
- GOSS 0.05
- MACD
- TEI -0.01
- GOSS -0.01
- Stochastic Oscillator
- TEI 10.32
- GOSS 0.00
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments and Money Market Funds.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.